Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents

Abstract excerpt

Potential conflict of interest: Nothing to report. To the Editor: The large majority of new direct antiviral agents (DAAs) against hepatitis C virus (HCV) are not pangenotypic and show major differences in response rates and resistance patterns, depending on HCV genotype and/or subtype (i.e., 1a/1b).1 Therefore, in view of the (exceptionally) high cost of these treatments, the accurate assessment of HCV...